As with many great undertakings, the quest sometimes holds more than the find. In this issue, Messiaen et a1.l report a mutational "hotspot" in exon lob of the NFI gene. As part of their analysis, 5 of 9 mutations involve a cDNA substitution (A1466G) that predicts a missense mutation (Y489C). However, the substitution of a guanosine at this position creates a splice donor site, which deletes the last 62 bases of exon lob resulting in a stop codon at amino acid-position 489. The other 4 mutations include a frame-shift C insertion ( 146511466) resulting in a stop codon at position 489, a 4-bp deletion in intron lob leading to exon dropout of lob, which would delete 45 amino acids if a stable protein were translated, and 2 with a T1523C substitution resulting in a L508P missense mutation. Even though the last 2 mutations have not been proven to inactivate the NFI gene product, neurofibromin, their rarity in the unaffected population highly suggests they represent botzn fine mutations. All told, the authors screened a total of 232 individuals with NF1, and they identified 9 exon lob mutations. This exon represents approximately 1.6% of the NFI coding sequence, therefore there is a 2.4-fold increased mutation incidence in exon lob over the expected occurrence if mutations occurred randomly throughout the cDNA.
As mutation "hotspots" go, this observation is somewhat lukewarm; however, with respect to NFI, it is as hot as it gets. In a review chapter by Upahyaya and Cooper, two other "hotspots" have been identified.' Exon 31 harbors a CpG dinucleotide that undergoes a recurrent transition (C5839T) resulting in an R1947X codon and premature truncation of translat i~n .~-~ As reviewed by Upadhyaya and Cooper, 563 subjects were screened and 10 showed this specific mutation (20/0),' whereas another 10 mutations involving this exon have been identified in an additional 130 subjects,lO-l2 which tallies to 20 mutations in 693 subjects screened or an incidence of approximately 3%. Exon 37 harbors a 4 basepair region between nucleotides 6789 and 6792 that has been shown to be mutated in approximately 1.8% of subjects s~reened.~.I~-l' Other recurrent mutations are reviewed in Upadhyaya and Cooper, however their numbers do not constitute hotspots.' Thus, screening the NFl gene for whole-gene deletions (approximately 5% of screened individuals with NFI ) and exon-specific mutations in exons lob (4%), 31 (3%), and 37 (1.8%) would predict that one could identify approximately 14% of NFl germline mutations.
To put this observation into a better perspective, it is important to recognize our limitations in establishing the true denominator in calculations of mutation "hotspots." This would include the number of subjects screened, segment screened, type of mutation analysis, and rigor in demonstrating the variant to be disease-causing. Interestingly, there are a number of "coldspots" or NFl exons for which n o mutation has been ide~ltified (28% of all exons and 2I%, of NFl cDNA). These include exons 1, 2, 4a, 9, 14, 15, 19b, 25, 40, 43,46, 47, 48, 49, and the alternative splice exons 9a, 23a, and 48a.' Thus, the "relative risk" of harboring mutations in eson lob would be less if one subtracts the number of bases representing esons that have never been shown to have a n~utation. In such a calculation, the overall expected percentage of mutations in lob becomes approximately 2% ( 135 bases in eson lob16792 bases in the cDNA esons with mutations) rather than 1.6% (135 bases in exon lob18601 total cDNA bases). The mutation incidence then goes from a 2.4-fold increase to a 1.95-fold increase over what is expected if the mutations were evenly distributed in a random fashion. This analysis suggests that eson lob harbors more mutations than expected when both RNA and geno~nic DNA are screened, yet considering the relative lack of lob mutations in the NNFF International NFl Genetic Analysis Consortium, it still does not provide us with the Holy Grail. Mutational hotspots are useful \vhrn identified; however, they need to be carefully defined. As demonstrated by this example, the denominator is an important but often dificult number to determine when one attempts to define the incidence of recurrent mutations.
The outstanding ~a l u e ofthe report in this issue by Messiaen et a1.I lies in the process by which they screened the NFI gene. Initially the authors screened those subjects for \rhom lymphoblastoid cell lines were available to perform the Protein Truncation Test (PTT) on total RNA freshly extracted from cell lines. Using random-primed RT-PCR to gener,lte cDNA segments for in vitro transcription and translation (IVTT), they identified 2 of 37 subjects who had an identical sizeshifted peptide in segment 1 (esons 1 through l'b). Upon further analysis they showed that one mutation was a frameshift termination and another was a termination due to aberrant splicing, both involving eson lob. They then screened 195 subjects at the genomic DNA level for eson lob mutations and identified 7 other mutations, 4 identical to the A1466G substitution. As pointed out in the discussion, there is some value in screening both RNA and DNA in determining the n~o l e c u l a~ etiology of the mutation. In the case of the aberrant splice donor site in exon lob, one could have assumed that a nlissense mutation defined at the genomic DNA sequence leilel would alter the peptide configuration, whereas, by cDNA analysis it was shown to be a disease-causing mutation due to premature truncation. This is not a novel mutation mechanism, ne\rerthe-less it points out the need to fully screen aberrant genonlic DNA sequence variants for filnctio~lal alterations at both the Genetics I -'
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-, / Viskochil inRNA and protein levels. Unfortunately, analysis of the peptide function is not available in the clinical setting, but mRNA can, and should be evaluated as part of screening protocols. Indeed, the NNFF International NFI Genetic Analysis Consortium includes a number of IIIRNA splicing mutations, 17 reported in 1 1 published studies,' and, given that NFI mRNA has not been screened routinely, it is likely that substantial percentage of NFI mutations result tiom &errant splicing due to mutations in esons in addition to introns, as shown in this report. ' Although essential in comprehensive mutation analysis, NFI cDNA screening still falls short in one important arena, and it is exemplified in the Messiaen et a1.l report. The authors h~v e not yet had the opportunity to determine the status of splicing of the A1466G mutation in tissue that represents the NF1 phenotype. It will be imperative to screen tissue from the subjects who harbor this mutation, as it becomes available, to demonstrate that the aberrant splicing of NFI primary transcript in lymphocytes, which is a tissue not involved in the NFl phenotype, is also aberrantly spliced in NF1-affected tissue. Such a recommendation is not restricted to this report or to NF1 in general, but applies to most genes that are screened for mutations using lymphocyte or some other ectopic RNA expressed from tissue that is not usually involved in the phenotype of the disorder.
Regardless of the nature of NFI mutations and their incidence in a gene that is commonly mutated in the human population, one must still ask, of what value is this information? Clearly, it is an important step in assessing genotype-phenotype correlations and in providing insight toward the pathophysiology of NF1. But, in this age of managed health care and shrinking research dollars, is NFl mutation detection a worthwhile endeavor? I posit that knowledge of the NFI mutation plays a minimal, if any, role in clinical management of affected families. Hotspots or not, mutation detection does not provide insight that physical examination and experienced genetic counseling does not already provide. NFl remains a clinical diagnosis based on tried and true criterialh that have been confirmed as valid and useful.17 The few instances in which knowledge of the constitutional mutation modifies clinical management does not warrant the use of clinical and research dollars to satisfy a "need to know." In some instances, presymptomatic testing in families in which the mutation is known could alter the early childhood surveillance of childhood complications, especially optic nerve gliomas. However, most medical centers are no longer performing routine MRI screening unless there are ophthalmological or neurological symptoms. The tradeoff of clinically following at-risk individuals through age 10 years, which includes dealing with the anxiety raised by the possibility of having a diagnosis with age-dependent onset of signs, should be weighed carefully against the value of NFI mutation detection screening as a diagnostic test. Presently, a concerted effort toward a hypothesis-driven, protocol-based approach to address specific questions regarding the pathophysiology of NFl is preferable to broad-based, unfocused NFI mutation screening, even if performed in the research arena.
In closing, Messiaen et a1.l have clearly demonstrated the importance of screening NFI mutations at both the RNA and DNA level, and they have identified a recurrent mutation that may be important in streamlining mutation analysis. They, like others, could not detect a genotype-phenotype correlation with respect to NFI mutations involving exon lob. Their work points out the importance of looking elsewhere, beyond the NFI mutant allele and with other techniques, to explain the variability of clinical expression of this complex and intriguing condition.lx In addition, it shows the difficulty in presenting complete phenotypes of subjects enrolled from multiple centers as part of a comprehensive report to be published in journals that are competitive for space. Nevertheless, to be most effective, a presentation of phenotypes, including both positive and negative findings, with respect to age would be important in compiling the compendium needed to exhaustively examine, and maybe put to rest, the notion that any exon-specific NFl mutation plays a significant role in genotype-phenotype correlation. Hopefully, a format that encourages the collection and reporting of robust phenotype analysis of genetic conditions can be developed in this age of electronic publishing to assist in engaging the collective readership in searching for the Holy Grail, in this instance genotype-phenotype correlation.
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